(6-methoxy-3-oxo-indan-1-yl)-acetic acid methyl ester | 25574-42-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (6-methoxy-3-oxo-indan-1-yl)-acetic acid methyl ester
• 英文别名: methyl 5-methoxy-1-oxoindan-3-acetate；(6-methoxy-3-oxoindan-1-yl)acetic acid methyl ester；Methyl 5-methoxyindan-1-one-3-acetate；methyl 2-(6-methoxy-3-oxo-1,2-dihydroinden-1-yl)acetate
• CAS: 25574-42-9
• 化学式: C₁₃H₁₄O₄
• 分子量: 234.252
• InChiKey: XXYJMAJGBMPORY-UHFFFAOYSA-N

物化性质

• 沸点：
  352.5±42.0 °C(Predicted)
• 密度：
  1.191±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (6-methoxy-3-oxo-indan-1-yl)-acetic acid methyl ester 在 一水合肼 作用下， 以 丙醇 为溶剂， 反应 6.0h， 以72%的产率得到2-(6-methoxy-3-oxo-1,2-dihydroinden-1-yl)acetohydrazide
  参考文献：
  名称：

  Pramanik, S. S.; Mukherjee, A., Journal of the Indian Chemical Society, 1998, vol. 75, # 1, p. 53 - 54

  摘要：

  DOI：
• 作为产物：
  描述：

  甲醇 、 5-甲氧基-1-茚酮-3-乙酸 在 硫酸 作用下， 以93%的产率得到(6-methoxy-3-oxo-indan-1-yl)-acetic acid methyl ester
  参考文献：
  名称：

  有效的乙酰胆碱酯酶抑制剂的合成，拆分和构效关系：8-carbaphysostigmine类似物。

  摘要：

  报道了一系列1,2,3,3a，8,8a-六氢茚并[2,1-b]吡咯5-烷基氨基甲酸酯的合成及其拆分。这些化合物在结构上与毒扁豆碱相关，只是取代了毒扁豆碱第8位的NMe基团，用亚甲基取代。与草毒碱相比，许多这些8-carbaphysostigmine类似物在体外是更有效的乙酰胆碱酯酶抑制剂，在体内毒性较小。（-）-对映体（例如1d和1g）在C3a和C8a处具有与毒扁豆碱相同的绝对构型，在抑制乙酰胆碱酯酶方面的效能比相应的（+）-对映体（例如， 1e和1h）。

  DOI：

  10.1021/jm00086a011

文献信息

• Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
  申请人：Peters Stefan

  公开号：US20110269791A1

  公开（公告）日：2011-11-03

  The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及由式（I）定义的化合物，其中A、B、X、m、n和o基团的定义如权利要求1中所述，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• Syntheses, resolution, and structure-activity relationships of potent acetylcholinesterase inhibitors: 8-carbaphysostigmine analogs
  作者：Yuhpyng L. Chen、Jann Nielsen、Kirk Hedberg、Audrey Dunaiskis、Shawn Jones、Lorena Russo、Jonathan Johnson、Jeffrey Ives、Dane Liston

  DOI：10.1021/jm00086a011

  日期：1992.4

  structurally related to physostigmine with substitution of a methylene group in place of the NMe group at position 8 of physostigmine. Many of these 8-carbaphysostigmine analogues are more potent acetylcholinesterase inhibitors in vitro and less toxic in vivo than physostigmine. The (-)-enantiomer (e.g., 1d and 1g) possessing the same absolute configuration at C3a and C8a as that of physostigmine, is about 6 to

  报道了一系列1,2,3,3a，8,8a-六氢茚并[2,1-b]吡咯5-烷基氨基甲酸酯的合成及其拆分。这些化合物在结构上与毒扁豆碱相关，只是取代了毒扁豆碱第8位的NMe基团，用亚甲基取代。与草毒碱相比，许多这些8-carbaphysostigmine类似物在体外是更有效的乙酰胆碱酯酶抑制剂，在体内毒性较小。（-）-对映体（例如1d和1g）在C3a和C8a处具有与毒扁豆碱相同的绝对构型，在抑制乙酰胆碱酯酶方面的效能比相应的（+）-对映体（例如， 1e和1h）。
• Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
  申请人：Himmelsbach Frank

  公开号：US20110190262A1

  公开（公告）日：2011-08-04

  The present invention relates to compounds defined by formula I wherein the groups R 1 to R 3 , X, m, n and o are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及公式I所定义的化合物，其中R1至R3、X、m、n和o的定义如权利要求书中所述，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以通过抑制该酶而受影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
  申请人：Himmelsbach Frank

  公开号：US08859580B2

  公开（公告）日：2014-10-14

  The present invention relates to compounds defined by formula I wherein the groups R1 to R3, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及公式I定义的化合物，其中R1至R3、X、m、n和o组的定义如权利要求书中所述，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，例如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
  申请人：Eckhardt Matthias

  公开号：US20110028445A1

  公开（公告）日：2011-02-03

  The present invention relates to compounds defined by formula (I) wherein the groups A, B, X, m, n and o are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及由式(I)定义的化合物，其中A，B，X，m，n和o的基团如权利要求1中所定义，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以通过抑制该酶而受到影响的疾病，如代谢性疾病，特别是2型糖尿病，肥胖症和血脂异常。